Anakinra treatment in schnitzler syndrome - Results of the first retrospective multi-center study in six patients from the Czech Republic;Léčba anakinrou u schnitzler-syndromu - Výsledky první retrospektivní multicentrické studie šesti pacientů z České republiky

Klinicka Onkologie

Volumn 27, Issue 2, 2014, Pages 111-126

  Szturz, Petr ^a   Sediva A ^b   Zurek M ^c   Adam, Z ^a   Stork J ^d   Cermakova Z ^e   Steyerova P ^d   Vokacova A ^d   Hrbek, J ^c   Sykora M ^f   Spicka I ^d   Mechl, Z ^a   Mayer, J ^a  

^a MASARYK UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^c PALACKÝ UNIVERSITY   (Czech Republic)

^d CHARLES UNIVERSITY   (Czech Republic)

^e UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^f Hospital eské Bud jovice   (Czech Republic)

Author keywords

Acute phase proteins; Anakinra; Interleukins; Monoclonal gammopathy; Osteogenesis; Schnitzler syndrome

Indexed keywords

ALPHA INTERFERON; ANTIHISTAMINIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CHLORAMBUCIL; CLADRIBINE; COLCHICINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GLUCOCORTICOID; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; THALIDOMIDE; ANTIRHEUMATIC AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ARTICLE; CLINICAL ARTICLE; CZECH REPUBLIC; GENE; GENETIC POLYMORPHISM; HUMAN; MALE; MULTICENTER STUDY (TOPIC); NLRP3 GENE; PUVA; REMISSION; RETROSPECTIVE STUDY; SCHNITZLER SYNDROME; IMMUNOLOGY;

ANTIRHEUMATIC AGENTS; CZECH REPUBLIC; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SCHNITZLER SYNDROME;

EID: 84899425226     PISSN: 0862495X     EISSN: 18025307     Source Type: Journal    
DOI: 10.14735/amko2014111     Document Type: Article

References (47)

1. Lipsker D. The Schnitzler syndrome. Orphanet J Rare Dis 2010; 5: 38.
2. Simon A, Asli B, Braun-Falco M et al. Schnitzler's syndrome: diagnosis, treatment, and follow-up. Allergy 2013; 68(5): S62-568.
3. Schnitzler L. Lésions urticariennes chroniques permanentes (érytheme pétaloide?) Cas cliniques, no 46 B. Journée Dermatologique d'Angers, 28 octobre 1972.
4. Schnitzler L, Schubert B, Boasson M et al. Urticaire chronique lesions osseuses macroglobulinémie IgM: Maladie de Waldenström? Bull Soc Fr Dermatol Syph 1974; 81: 363-366.
5. de Koning HD, Bodar EJ, van der Meer JW et al. Schnitzler syndrome: beyond the case reports: review and follow-up of 94 patients with an emphasis on prognosis and treatment Semin Arthritis Rheum 2007; 37(3): 137-148. (Pubitemid 350151505)
6. Jain T, Offord CP, Kyle R et al. Schnitzler syndrome: an under diagnosed clinical entity. Haematologica 2013; 98(10): 1581-1585.
7. Szturz P, Adam Z, Šedivá A et al. Schnitzler-syndrom: diagnostika a léčba. Klin Onkol 2011; 24(4): 271 -277.
8. Lipsker D, Veran Y, Grunenberger F et al. The Schnitzler syndrome. Four new cases and review of the literature. Medicine (Baltimore) 2001; 80(1): 37-44. (Pubitemid 32066377)
9. SanMartín O, Febrer I, Botella R et al. Urticarial lesions and monoclonal IgM gammopathy. Schnitzler's syndrome. Arch Dermatol 1994; 130(9): 1195-1198.
10. Kieffer C, Cribier B, Lipsker D. Neutrophilic urticarial dermatosis: a variant of neutrophilic urticaria strongly associated with systemic disease. Report of 9 new cases and review of the literature. Medicine (Baltimore) 2009; 88(1): 23-31.
11. Besada E, Nossent H. Dramatic response to IL1-RA treatment in longstanding multidrug resistant Schnitzler's syndrome: a case report and literature review. Clin Rheumatol 2010; 29(5): 567-571.
12. Loock J, Lamprecht P, Timmann C et al. Genetic predisposition (NLRP3 V198M mutation) for IL-1-mediated inflammation in a patient with Schnitzler syndrome. J Allergy Clin Immunol 2010; 125(2): 500-502.
13. Rowczenlo DM, Trojer H, Russell T et al. Clinical characteristics in subjects with NLRP3 V198M diagnosed at a single UK center and a review of the literature. Arthritis Res Ther 2013; 15(1): R30.
14. Terpos E, Asli B, Christoulas D et al. Increased angiogenesis and enhanced bone formation in patients with IgM monoclonal gammopathy and urticarial skin rash: new insight into the biology of Schnitzler syndrome. Haematologica 2012; 97(11): 1699-1703.
15. Szturz P, Adam Z, Klabusay M et al. Schnitzler-syndrom: popis případu, zkušenosti s léčbou glukokortikoidy a preparátem anakinra (Kineret™) a sledování cytokinové odpovědi organizmu. Vnitř Lék 2011; 57(1): 97-112.
16. Adam Z, Krejčí M, Pour L et al. Zhodnocení dvouleté léčby Schnitzlerova syndromu (kopř ivkové velkoplošní morfy, monoklonální IgM gamapatie a osteolyticko-osteosklerotické zmény skeletu) preparátem anakinra (Kineret). Vnitř Lék 2009; 55(12): 1196-1197.
17. Claes K, Bammens B, Delforge M et al. Another devastating complication of the Schnitzler's syndrome: AA amyloidosis. Br J Dermatol 2008; 158(1): 182-184. (Pubitemid 350221902)
18. Verret JL, Leclech C, Rousselet MC et al. Schnitzler syndrome and Waldenström disease. Fatal outcome of the original case. Ann Dermatol Venereol 1993; 120(6-7): 459-460. (Pubitemid 23212715)
19. Asli B, Brouet JC, Fermand JP. Spontaneous remission of Schnitzler syndrome. Ann Allergy Asthma Immunol 2011; 107(1): 87-88.
20. Martinez-Taboada VM, Fontalba A, Blanco R et al. Successful treatment of refractory Schnizler syndrome with anakinra: comment on the article by Hawkins et al. Arthritis Rheum 2005; 52(7): 2226-2227. (Pubitemid 40994347)
21. Flórez AF, Gallardo Agromayor E, García-Barredo R et al. Radiological aid to clinical diagnosis of Schnizler's syndrome: multimodality imaging approach. Clin Rheumatol 2008; 27(1): 107-110. (Pubitemid 50000809)
22. Sedivá A, Poloučková A, Podrazil M et al. Characterization of the B-cell compartment in a patient with Schnitzler syndrome. Scand J Rheumatol 2011; 40(2): 158-160.
23. Borradori L, Rybojad M, Puissant A et al. Urticarial vasculitis associated with monoclonal IgM gammopathy, Schnitzler's syndrome. Brit J Dermatol 1990; 123(1): 113-118. (Pubitemid 20226523)
24. Berdy SS, Bloch KJ. Schnitzler's syndrome: A broader clinical spectrum. J Allergy Clin Immunol 1991; 87(4): 849-854.
25. Olsen E, Forre O, Lea T et al. Unique antigenic determinants used as markers in a patient with macroglobulinemia urticaria. Similar idiotypes demonstrated in the skin and on peripheral blood lymphocytes. Acta Med Scand 1980; 207(5): 379-384. (Pubitemid 10117166)
26. Lebbe C, Rybojad M, Klein F et al. Schnitzler's syndrome with sensomotor neuropaty. J Amer Acad Dermatol 1994; 30(2 Pt 2): 316-318.
27. Eiling E, Möller M, Kreiselmaler I et al. Schnizler syndrome: treatment failure to rituximab but response to anakinra. J Am Acad Dermatol 2007; 57(2): 361-364. (Pubitemid 47048871)
28. Aikawa NE, Silva CA, Bonfá E et al. Schnitzler's syndrome improvement after anti-TNF-alpha therapy. Joint Bone Spine 2010; 77(5): 491.
29. de Koning HD, Bodar EJ, Simon A et al. Beneficial response to anakinra and thalidomide in Schnitzler's syndrome. Ann Rheum Dis 2006; 65(4): 542-544.
30. Asli B, Bienvenu B, Cordoliani F et al. Chronic urticaria and monoclonal IgM gammopathy (Schnitzler syndrome): report of 11 cases treated with pefloxacin. Arch Dermatol 2007; 143(8): 1046-1050. (Pubitemid 47296082)
31. Kastritis E, Katoulis A, Terpos E et al. Schnitzler's syndrome: increased levels of bone formation and angiogenesis factors are reduced after successful pefloxacin treatment. Clin Lymphoma Myeloma 2008; 8(6): 359-362.
32. Janier M, Bonvalet D, Blanc MF et al. Chronic urtica and macroglobulinemia (Schnitzler's syndrome): report of two cases. J Amer Acad Dermatol 1989; 20(2 Pt 1): 206-211. (Pubitemid 19055626)
33. Asahina A, Sakurai N, Suzuki Y et al. Schnitzler's syndrome with prominent neutrophil infiltration misdiagnosed as Sweet's syndrome: a typical example of urticarial neutrophilic dermatosis. Clin Exp Dermatol 2010; 35(4): e123-e126.
34. Migliorini P, Del Corso I, Tommasi C et al. Free circulating interleukin-18 is increased in Schnitzler syndrome: a new autoinflammatory disease? Eur Cytokine Netw 2009; 20(3): 108-111.
35. Pizzirani C, Falzoni S, Govoni M et al. Dysfunctional inflammasome in Schnitzler's syndrome. Rheumatology (Oxford) 2009; 48(10): 1304-1308.
36. Ryan JG, de Koning HD, Beck LA et al. IL-1 blockade in Schnitzler syndrome: ex vivo findings correlate with clinical remission. J Allergy Clin Immunol 2008; 121(1): 260-262.
37. Krause K, Feist E, Fiene M et al. Complete remission in 3 of 3 anti-IL-6-treated patients with Schnitzler syndrome. J Allergy Clin Immunol 2012; 129(3): 848-850.
38. Vitale A, Lucherini OM, Galeazzi M et al. Long-term clinical course of patients carrying the Q703K mutation in the NLRP3 gene: a case series. Clin Exp Rheumatol 2012; 30(6): 943-946.
39. Nuki G, Bresnihan B, Bear MB et al. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46(11): 2838-2846. (Pubitemid 35315874)
40. Stahl N, Radin A, Mellis S. Rilonacept-CAPS and beyond. Ann N Y Acad Sci 2009; 1182: 124-134.
41. Krause K, Weller K, Stefaniak R et al. Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study. Allergy 2012; 67(7): 943-950.
42. Church LD, McDermott MF. Canakinumab: a human anti-IL-1β monoclonal antibody for the treatment of cryopyrin-associated periodic syndromes. Expert Rev Clin Immunol 2010; 6(6): 831-841.
43. de Koning HD, Schalkwijk J, van der Meer JW et al. Successful canakinumab treatment identifies IL-1β as a pivotal mediator in Schnitzler syndrome. J Allergy Clin Immunol 2011; 128(6): 1352-1354.
44. Vanderschueren S, Knockaert D. Canakinumab in Schnitzler syndrome. Semin Arthritis Rheum 2013; 42(4): 413-416.
45. Ščudla V, Budíková M, Petrová P et al. Analýza sérových hladin vybraných biologických ukazatelů u monoklonální gamapatie nejistého významu a mnohočetného myelomu. Klin Onkol 2010; 23(3): 171-181.
46. Paglia F, Dionisi S, De Geronimo S et al. Biomarkers of bone turnover after a short period of steroid therapy in elderly men. Clin Chem 2001; 47(7): 1314-1316. (Pubitemid 32579125)
47. Engvall IL, Svensson B, Tengstrand B et al. Impact of low-dose prednisolone on bone synthesis and resorption in early rheumatoid arthritis: experiences from a two-year randomized study. Arthritis Res Ther 2008; 10(6): R128.